HC Wainwright Brokers Reduce Earnings Estimates for Arvinas

Key Points

• HC Wainwright cut its Q1 2026 EPS estimate for Arvinas from ($0.89) to ($0.96) and now forecasts FY2026 EPS of ($3.93), while projecting gradual improvement to $0.04 EPS by FY2030.
• Arvinas' latest quarter (reported Feb. 24) missed expectations, posting ($1.10) EPS vs. a ($0.55) consensus and revenue of $9.5M vs. $37.26M, an 84% year-over-year revenue decline.
• The stock trades around $10.61 (52-week range $5.90–$14.51) with a MarketBeat consensus rating of "Hold" and an average price target of $14.60, and insiders have both bought (director 20,000 shares) and sold (CEO 4,786 shares) recently.

Arvinas, Inc. (NASDAQ:ARVN - Free Report) - Equities research analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Arvinas in a research report issued to clients and investors on Monday, May 4th. HC Wainwright analyst A. Fein now forecasts that the company will earn ($0.96) per share for the quarter, down from their prior forecast of ($0.89). The consensus estimate for Arvinas' current full-year earnings is ($3.21) per share. HC Wainwright also issued estimates for Arvinas' Q2 2026 earnings at ($0.95) EPS, Q3 2026 earnings at ($1.01) EPS, Q4 2026 earnings at ($1.01) EPS, FY2026 earnings at ($3.93) EPS, FY2027 earnings at ($2.20) EPS, FY2028 earnings at ($3.28) EPS, FY2029 earnings at ($1.10) EPS and FY2030 earnings at $0.04 EPS.

Arvinas (NASDAQ:ARVN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($1.10) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.55). The company had revenue of $9.50 million for the quarter, compared to analysts' expectations of $37.26 million. Arvinas had a negative return on equity of 14.25% and a negative net margin of 30.77%.The business's quarterly revenue was down 84.0% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.63) EPS.

ARVN has been the subject of a number of other research reports. Citigroup upped their price objective on shares of Arvinas from $21.00 to $24.00 and gave the company a "buy" rating in a report on Monday. Piper Sandler reaffirmed an "overweight" rating and set a $20.00 target price (up from $16.00) on shares of Arvinas in a research note on Wednesday, February 25th. Truist Financial set a $10.00 target price on shares of Arvinas in a report on Wednesday, March 18th. BTIG Research increased their price target on shares of Arvinas from $14.00 to $16.00 and gave the company a "buy" rating in a research note on Thursday, March 19th. Finally, Wedbush raised their price target on shares of Arvinas from $9.00 to $11.00 and gave the stock a "neutral" rating in a report on Tuesday, February 24th. Nine equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $14.60.

Arvinas Stock Down 1.6%

Shares of ARVN opened at $10.61 on Wednesday. Arvinas has a 52-week low of $5.90 and a 52-week high of $14.51. The stock has a fifty day simple moving average of $11.51 and a two-hundred day simple moving average of $11.67. The company has a market capitalization of $684.56 million, a PE ratio of -8.29 and a beta of 1.79.

Insider Buying and Selling at Arvinas

In related news, Director Briggs Morrison bought 20,000 shares of the firm's stock in a transaction on Friday, March 6th. The shares were bought at an average price of $13.40 per share, with a total value of $268,000.00. Following the completion of the transaction, the director directly owned 96,021 shares of the company's stock, valued at $1,286,681.40. This represents a 26.31% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Randy Teel sold 4,786 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $12.16, for a total transaction of $58,197.76. Following the transaction, the chief executive officer directly owned 149,696 shares of the company's stock, valued at approximately $1,820,303.36. This trade represents a 3.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 63,864 shares of company stock worth $802,443. Insiders own 4.73% of the company's stock.

Hedge Funds Weigh In On Arvinas

Several large investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC increased its holdings in Arvinas by 491.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,819 shares of the company's stock valued at $43,000 after purchasing an additional 4,835 shares during the last quarter. Canada Pension Plan Investment Board raised its position in Arvinas by 109.4% in the second quarter. Canada Pension Plan Investment Board now owns 6,700 shares of the company's stock valued at $49,000 after purchasing an additional 3,500 shares during the period. State of Wyoming acquired a new position in Arvinas during the third quarter worth $68,000. Aster Capital Management DIFC Ltd purchased a new position in shares of Arvinas during the third quarter worth $92,000. Finally, Jain Global LLC acquired a new stake in shares of Arvinas in the third quarter valued at $95,000. 95.19% of the stock is currently owned by institutional investors and hedge funds.

About Arvinas

Arvinas, Inc NASDAQ: ARVN is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body's natural protein-recycling systems.

The company's most advanced clinical candidates address hormone-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.